FAQs

There is no fee to join Infinity Infusion Solutions. IIS membership is complimentary and designed to give independent infusion providers access to valuable contracting opportunities, industry expertise, resources, and ongoing support without an upfront membership cost.

IIS membership is designed for U.S. healthcare providers that administer buy-and-bill infusion and injectable therapies. This includes independent physician practices, Ambulatory Infusion Centers (AICs), multi-specialty infusion clinics, and other independent providers delivering specialty infusion care.

Our team can help determine whether IIS membership is the right fit for your organization.

IIS supports infusion providers across a range of therapeutic specialties, with a focus on Allergy/Immunology, Neurology, Rheumatology, Gastroenterology, and Oncology/Hematology, in addition to other areas that utilize IVIG, biologics, and specialty infusion therapies.

Our manufacturer relationships and growing specialty drug portfolio help independent infusion providers navigate access and purchasing opportunities across multiple disease states and therapeutic areas.

IIS members receive access to competitive specialty drug contracting and pricing, industry insights, reporting and analytics, new infusion suite launch support and assistance navigating drug access and distribution.

Beyond purchasing, members receive personalized guidance and resources designed to help optimize operations, understand market changes, support patient access, and build sustainable infusion programs.

Simply book a consult with a member of our sales team to discuss your organizational needs and business objectives. IIS is here to serve as a partner and consultant, and to build a customized plan that is aligned with your corporate goals now and in the future.

Applying for IIS membership is straightforward. Providers can complete the IIS membership application, and a member of our team will follow up to learn more about the organization and guide you through next steps.

IIS provides a high-touch, responsive support model built around the needs of independent infusion providers. Members can turn to our team for assistance navigating drug access, reimbursement considerations, pricing changes, distribution issues, new infusion suite launch support, industry trends, and other operational challenges.

Our goal is to be an accessible, dependable partner—not simply a source for drug contracts.

A traditional healthcare group purchasing organization, or GPO, uses the collective purchasing volume of its members to negotiate contracts with manufacturers, distributors, and other suppliers. While this model can create purchasing efficiencies, traditional GPOs are often built around broad contract portfolios and transaction volume rather than the specialized needs of an individual infusion practice. Industry concerns have also centered on complex contracting structures, limited transparency, and vendor-funded administrative fees that can create questions about whether incentives are always fully aligned with providers.

IIS is not a traditional GPO. We are a high-touch medical consultancy focused specifically on independent infusion providers. Competitive drug contracting is only one part of what we do. IIS combines access to manufacturer agreements with personalized reimbursement support, drug access guidance, market intelligence, analytics, distribution support, and direct industry expertise.

Our team works closely with each member to understand their therapeutic focus, patient population, operational needs, and business goals. The result is a relationship designed around provider success and sustainable patient access—not simply purchasing volume.

IIS helps independent infusion providers access competitive specialty drug contracting while providing the guidance and resources needed to navigate an increasingly complex infusion marketplace.

Through relationships with manufacturers, distributor partners, and infusion providers, IIS helps members address drug access, reimbursement considerations, pricing, distribution, market changes, and other business challenges while maintaining their independence.

IIS works with a broad network of national and specialty distributors, including:

• Cencora / Besse Medical
• Cardinal Health
• FFF Enterprises
• Prodigy Health

IIS works on behalf of our members to negotiate and support the contracting, pricing, access, and program benefits available across these relationships. Our multi-distributor network then gives members greater flexibility in how they purchase and access the therapies they need, allowing them to work through the distributor relationships that best fit their practice, product needs, and operational preferences.

The result is greater choice, flexibility, and access—backed by the high-touch IIS support members rely on to navigate purchasing decisions and maximize the value of the agreements negotiated on their behalf.

Buy-and-bill is a reimbursement model in which a healthcare provider purchases a medication, administers it to a patient, and then submits a claim to the appropriate payer for reimbursement.

For independent infusion providers, successful buy-and-bill operations require careful attention to drug acquisition cost, inventory, coding, payer requirements, reimbursement, and payment timing. IIS supports buy-and-bill providers through competitive contracting, reimbursement and market insights, and drug access support.

Buy-and-bill allows infusion providers to purchase and manage medications directly and maintain greater control over drug procurement, inventory, and the treatment process.

At the same time, providers assume the financial and operational responsibility associated with purchasing medications, maintaining inventory, meeting payer requirements, submitting claims, and receiving reimbursement. IIS helps members better understand the purchasing and market factors that can affect the sustainability of their infusion programs.

A J-code is a type of HCPCS Level II code used to identify many drugs and biological products administered by healthcare providers.

For independent infusion practices, the appropriate HCPCS or J-code is an important part of accurate billing and reimbursement. Providers must also consider billing units, modifiers, payer requirements, and effective dates when submitting claims.

Infusion providers use the applicable HCPCS code, including J-codes for many provider-administered therapies, when submitting claims for reimbursement. Because coding, reimbursement, and payer requirements can change, staying ahead of regulatory updates is critical to avoiding operational and reimbursement disruption.

IIS helps members stay informed through industry insights, reimbursement resources, and long-standing strategic partnerships with advocacy organizations including the National Infusion Center Association (NICA) and the Infusion Providers Alliance (IPA).

IIS takes a proactive approach to keeping members informed about regulatory and reimbursement changes that may affect independent infusion practices.

Through our long-standing partnerships with NICA and IPA, IIS connects members directly with organizations working on the issues shaping the infusion industry. Twice each year, IIS hosts member Town Halls featuring IPA to review important regulatory and reimbursement developments before they take effect, helping providers understand what is changing and how those changes may affect their practices.

These sessions also create an open forum where IIS members can ask provider-specific questions directly to industry advocacy experts, giving them practical context to help prepare their organizations for what comes next.

CMS updates the HCPCS code set throughout the year, including codes for drugs and biological products. These updates can include new codes, changes to existing codes, revised drug descriptors, billing units, and related payment information.

Because even small coding changes can have meaningful reimbursement implications, IIS works to help members understand relevant changes before implementation. Through ongoing industry monitoring and our partnerships with NICA and IPA, members receive timely education and opportunities to engage directly with advocacy experts on regulatory developments affecting independent infusion providers.

Providers can verify current CMS and payer guidance here before submitting claims.

Intravenous immunoglobulin, commonly called IVIG, is an immune globulin therapy administered intravenously. Immune globulin products are manufactured from donated human plasma and contain antibodies that can be used for antibody replacement and to modify immune-system activity in certain conditions.

For infusion providers administering IVIG, product access, availability, acquisition cost, payer requirements, reimbursement, and inventory management can all be important considerations. IIS has deep experience helping independent infusion providers navigate the IVIG marketplace.

Visit the FDA for current immune globulin safety and availability updates.

From primary immunodeficiencies such as CVID, to neurological conditions like CIDP, autoimmune diseases such as dermatomyositis, hematologic conditions including ITP, and many conditions in between, IVIG is used across a broad range of specialties..

Providers should refer to the current FDA-approved prescribing information for each specific IVIG product when determining approved indications and appropriate use.

IIS works with a broad portfolio of intravenous and subcutaneous immune globulin therapies. The current IIS portfolio includes IVIG products such as Octagam, Privigen, Gammagard Liquid, Bivigam, Panzyga, Gamunex-C, and Asceniv, as well as subcutaneous immune globulin therapies including Hizentra, Cutaquig, and HyQvia.

IIS helps members navigate applicable contracting, purchasing, access, and distribution opportunities across its immune globulin portfolio.

IVIG access can be affected by product availability, manufacturing capacity, demand, distribution, and other supply-chain factors. When supply becomes constrained, infusion providers may need to carefully manage inventory and evaluate available product options to help maintain continuity of patient care.

IIS uses its relationships across the manufacturer and distribution landscape to help members navigate IVIG access and availability when challenges arise.

A biosimilar is a biological product that is highly similar to an FDA-approved reference biologic and has no clinically meaningful differences in safety and effectiveness.

As more biosimilars enter specialty infusion, providers may encounter additional choices involving payer coverage, reimbursement, acquisition cost, product availability, and access. IIS helps members stay informed as this market continues to evolve.

A biologic is a medication produced from living sources. A biosimilar is also a biologic, but it is developed to be highly similar to an already-approved reference biological product.

Biosimilars are not identical copies of reference biologics, but FDA requires them to have no clinically meaningful differences in safety and effectiveness.

An interchangeable biosimilar is a biosimilar that has met additional FDA requirements associated with pharmacy-level substitution for its reference product, subject to applicable state law.

For infusion providers, interchangeability is one consideration among many. Payer policies, prescribing requirements, reimbursement, product availability, clinical indications, and state requirements may also influence product use.

The growing number of biosimilars is increasing competition and expanding the number of biologic treatment options available to providers and patients.

For independent infusion providers, this evolving market creates additional considerations around acquisition cost, reimbursement, payer preferences, and product access. IIS helps members stay informed and evaluate applicable purchasing opportunities as the specialty infusion landscape changes.

Explore FDA resources on biosimilars and interchangeability here.

IIS works with pharmaceutical manufacturers as a strategic partner to improve therapy access and support market objectives within the independent infusion channel.

Depending on the therapy and manufacturer goals, IIS can support provider network strategy, contract administration and compliance, provider education, reimbursement and access initiatives, and market intelligence—helping connect manufacturers with the providers serving appropriate patient populations.

IIS helps manufacturers build effective pathways into the independent infusion market by leveraging our national provider network, infusion expertise, and understanding of site-of-care dynamics.

For new therapy launches, IIS can support provider identification and access strategy, targeted education, reimbursement awareness, contracting, and programs designed to help appropriate providers successfully integrate a therapy into practice.

IIS works closely with independent infusion providers to help identify and address barriers that can affect therapy access and continuity. This can include provider education around reimbursement, connections to applicable patient financial assistance resources, and programs designed to support treatment initiation and ongoing access.

Our strong provider relationships give manufacturers a direct connection to the real-world access challenges experienced within the infusion setting.

IIS works with a national network of over 2,700 member infusion sites, including independent physician practices, ambulatory infusion centers, and multi-specialty infusion clinics.

This network gives manufacturers access to a diverse range of independent infusion settings and enables IIS to develop targeted provider and site-of-care strategies based on the needs of each therapy.

IIS uses purchasing, utilization, and market data to turn complex information into actionable insights that help our partners make more informed decisions.

For providers, these insights can create greater visibility into their business, identify opportunities, and support stronger operational and financial performance. For manufacturer partners, IIS data can help illuminate market trends, network performance, provider behavior, and opportunities to strengthen therapy access and engagement.

And we’re continuing to take that visibility even further. IIS is investing in next-generation technology, including CompassIQ™, designed to give independent infusion providers smarter operational tools, deeper visibility, actionable analytics, and greater insight into practice performance. More to come as CompassIQ launches in the back half of 2026.